Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventional

Distress Associated With Stopping Immunotherapy of Cancer Patients

NCT ID: NCT04761328Sponsor: University of PittsburghLast updated: 2025-12-05

Summary

The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.

Detailed description

The intervention will be delivered through telemedicine to reduce the patient-related barriers to treatment including cost, transportation, and being able to maintain appointments while managing the side effects of treatment. The intervention will provide the patient with skills to reduce distress associated with ceasing treatment of a checkpoint inhibitor through the development evidence-based psychological and behavioral strategies that are tailored to the patients' preferences.

Arms & interventions

  • Behavioralcognitive behavioral therapy

    Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.

Outcome measures

Primary

  • Reduce fear of recurrence

    Change by 50%

    Time frame: 3 months

Secondary

  • Improve quality of life

    Time frame: 3 months

  • Reduction of anxiety

    Time frame: 3 months

  • Depressive symptoms

    Time frame: 3 months

Eligibility criteria

Sex: AllAge: 21 Years and olderHealthy volunteers: No
Inclusion Criteria: * Age 21 years and older * Fluent in English * Diagnosis of cancer and history of treatment with immunotherapy Exclusion Criteria: * Active suicidal ideation, delusions or hallucinations

Study locations (1)

UPMC Hillman Cancer Centers

Pittsburgh, Pennsylvania, 15213

Recruiting
Jennifer L Steel, Ph.D. · Contact